Symbols

IMVT

Immunovant·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IMVT

Immunovant, Inc.

A clinical-stage biopharmaceutical company that developing therapies for autoimmune diseases

Industry

Pharmaceutical

Established Date

12/06/2018

Listing Date

06/21/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

362

Fiscal Year Ends

03-31

Website

www.immunovant.com

Security Type

Common stock

Office address

1000 Park Forty Plaza, Suite 210, Durham, NC 27713

Business

Introduction

Immunovant, Inc., incorporated in Delaware on December 6, 2018, is a clinical-stage biopharmaceutical company focused on providing a normal life for patients with autoimmune diseases.

Company Financials

EPS

IMVT has released its 2026 Q3 earnings. EPS was reported at -0.61, versus the expected -0.72, beating expectations. The chart below visualizes how IMVT has performed over recent quarters, highlighting trends in earnings surprises.